Literature DB >> 29578885

Analysis of Opioid Use Following Curative Cancer Treatment at a Large Urban Safety-net Hospital.

Amanda S Cass1, Joyce T Alese2, Chaejin Kim3, Marjorie A Curry4, Jennifer A LaFollette4, Zhengjia Chen3, Olatunji B Alese4,5.   

Abstract

OBJECTIVES: This study examined the pattern of use and factors predicting prolonged prescription opioid medications among cancer patients following treatment with curative intent.
MATERIALS AND METHODS: Patients diagnosed with cancer over a 3-year period at a large urban safety-net hospital were included. Univariate and multivariate analyses was used to identify factors associated with continued opioid use.
RESULTS: Of the 199 patients included in the study, 38% continued to receive an opioid prescription well beyond the acute diagnosis and treatment phase. Mean age was 60.3 years, with a female preponderance (63%). Surgical resection only (31.6%) and the combination of surgery, chemotherapy, and radiation (19.7%) were the commonest treatment modalities. Pain-related comorbidities predating cancer diagnosis were reported in 53.3% of the patients, and about 33% were also on pain-modifying medications (odds ratio [OR], 3.58; 95% confidence interval [CI], 1.92-6.77; Fisher exact test P<0.001). Average number of prescriptions received per patient was 4.8 (range, 1 to 31), over an average of 9.5 months (range, 1.2 to 28.1 mo). Mean morphine milligram equivalents prescribed per prescription was 319 mg (range, 48 to 2475 mg). According to multivariate model, patients who received chemotherapy (OR, 7.25; 95% CI, 2.09-25.17; P=0.0018), or pain-modifying medications (OR, 4.61; 95% CI, 2.25-9.44; P<0.0001) were significantly more likely to continue to receive prescriptions for opioids. DISCUSSION: Treatment with chemotherapy, pain-modifying medications, cancer stage, and interval between diagnosis and treatment are the best predictors for continuous opioid use. The current epidemic of opioid misuse and abuse makes examination current practices and identifification of areas of improvement imperative.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29578885     DOI: 10.1097/AJP.0000000000000612

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  3 in total

1.  New-onset persistent opioid use following breast cancer treatment in older adult women.

Authors:  Andrew W Roberts; Nicole Fergestrom; Joan M Neuner; Aaron N Winn
Journal:  Cancer       Date:  2019-12-17       Impact factor: 6.860

2.  Long-term opioid use in curative-intent radiotherapy: One-Year outcomes in head/neck cancer patients.

Authors:  Leif-Erik D Schumacher; Zoukaa B Sargi; Melissa Masforroll; Deukwoo Kwon; Wei Zhao; Maria A Rueda-Lara; Laura M Freedman; Nagy Elsayyad; Stuart E Samuels; Matthew C Abramowitz; Michael A Samuels
Journal:  Head Neck       Date:  2019-11-30       Impact factor: 3.147

3.  Risk of Persistent Opioid Use following Major Surgery in Matched Samples of Patients with and without Cancer.

Authors:  Mary Falcone; Chongliang Luo; Justin E Bekelman; Caryn Lerman; Yong Chen; David Birtwell; Martin Cheatle; Rui Duan; Peter E Gabriel; Lifang He; Emily M Ko; Heinz-Josef Lenz; Nebojsa Mirkovic; Danielle L Mowery; E Andrew Ochroch; E Carter Paulson; Emily Schriver; Robert A Schnoll
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-28       Impact factor: 4.254

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.